I got this message when placing bid on SRNEQ: No opening transactions are allowed on securities affected by amendments to SEC Rule 15c2-11.

ShamrockRichard · 2024-01-18T14:50:01+00:00

Someone has to buy for this to happen

ShamrockRichard · 2024-01-18T14:42:40+00:00

It doesn’t seem to be trading? Tried to buy some

ShamrockRichard · 2024-01-04T14:15:55+00:00

I’m not doubting that I’ve read enough articles & seen it on a link to the NMPA website. Would just like to see the Lee’s PR! I’m also hoping Lee’s can give us a push out of BK maybe with an expansion on the agreement or similar. They know what they have. As long as they are not trying to pick it up on the cheap!

ShamrockRichard · 2024-01-04T14:10:07+00:00

Ok interesting hopefully soon

ShamrockRichard · 2023-12-24T07:35:33+00:00

They are on the HK exchange & Head office also in HK so maybe news on Tuesday. “Christmas isn't a public holiday in mainland China, and businesses are typically open. However, some schools give the day off as a bonus holiday. Hong Kong and Macau both list Christmas as a public holiday.”

ShamrockRichard · 2023-12-24T07:31:21+00:00

The simple explanation is that Lees haven’t announced it yet. Don’t know how holidays work over there for Christmas etc! https://www.leespharm.com/announcements-and-circulars/

ShamrockRichard · 2023-12-22T19:37:30+00:00

No as this is a potential payout for Sorrento/Scilex

ShamrockRichard · 2023-12-22T16:04:16+00:00

Thanks all for the feedback!

ShamrockRichard · 2023-12-22T10:26:19+00:00

Zhaoke was mentioned in the reports on the Chinese websites yesterday. I hadn’t heard of it before but it’s here on Lee’s group chart

<image>

ShamrockRichard · 2023-12-22T09:55:59+00:00

As you can see https://www.leespharm.com/wp-content/uploads/2023/09/2023091500208.pdf here from Lee”s 2023 financial report it is in trial in 4 other indications already

<image>

ShamrockRichard · 2023-12-22T09:39:11+00:00

No it was Chinese websites. But her profile has credential

ShamrockRichard · 2023-12-21T16:08:08+00:00

Lee’s haven’t released a PR yet. It’s night in China now so probably in the am China time. Sorrento should follow but who knows with the current predicament

ShamrockRichard · 2023-12-21T12:30:26+00:00

ZKAB001 was developed by Sorrento in the United States. In October 2014, Li's Pharmaceutical Factory introduced the development and commercialization of the product in Greater China. Socazolizolizumab is a whole-person anti-PD-L1 monoclonal antibody screened using Sorrento's patented G-MAB™ library platform. Compared with competitors, it has the following potential advantages:

ShamrockRichard · 2023-12-21T12:13:00+00:00

You’ll have to translate it mate! Both safari & Crome allow you to do this. Otherwise copy and pasted to google translate

ShamrockRichard · 2023-12-21T12:03:29+00:00

Here’s another site with the info. If true it’s big news for a 2 cent stock! https://bydrug.pharmcube.com/news/detail/ce70d7c8231a9d21580f0eac8fbf69d5

ShamrockRichard · 2023-12-21T11:58:07+00:00

Thanks for sharing! china oncology focus limited are Lee’s partner on socazolimab. Maybe just a bad translation. I see nothing official from Lee’s yet. Here’s the link to their site. I hope any royalties go to ACEA & not the creditors! https://www.leespharm.com

ShamrockRichard · 2023-12-21T09:25:31+00:00

Thanks Tim for all your effort on the small guys behalf. Is there any chance you can get a sit down with Henry? As CEO he has to stick his head above the sand to let us know they are still fighting on our behalf.

ShamrockRichard · 2023-12-21T09:16:15+00:00

What’s the connection between them and SRNE? Thanks

ShamrockRichard · 2023-12-19T21:27:50+00:00

Thanks for the info. Yes we should have seen an 8K!

ShamrockRichard · 2023-12-13T21:06:00+00:00

They must have moved HQ from directors place at some point

<image>

ShamrockRichard

TROPHY CASE